FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885128417> ?p ?o ?g. }

• W2885128417 endingPage "2776" @default.
• W2885128417 startingPage "2776" @default.
• W2885128417 abstract "Abstract Studies have demonstrated that the clinical benefit of PD-1 blockade can be further improved by combination with an αCTLA-4 mAb in some indications. However, this increased activity is commensurate with significant immune related adverse events (irAE's). Therefore, novel approaches are required to uncouple toxicity from anti-tumour efficacy and realise the full potential of this combination. MEDI5752 is a monovalent bispecific human IgG1 monoclonal antibody (mAb) with an engineered fragment crystallisable (Fc) domain to reduce Fc effector function, that specifically binds two clinically validated negative T cell regulators; PD-1 (programmed cell death 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). MEDI5752 has been designed to suppress the PD-1 pathway and provide modulated CTLA-4 inhibition to uncouple CTLA-4 dependent peripheral toxicity from tumour efficacy. PD-1 expression is a defining feature of tumour infiltrating lymphocytes (TILs). We show that MEDI5752 can saturate CTLA-4 on PD-1+ cells at orders of magnitude lower concentrations than required to saturate CTLA-4 on PD-1- cells. Moreover, our data demonstrate that monovalent targeting of CTLA-4 with MEDI5752 is significantly less potent (15 fold) than bivalent targeting with a parental αCTLA-4 mAb in reporter assays. In contrast, the switch to monovalent targeting of PD-1 has limited effect on potency (within 3-fold compared to a parental αPD-1 mAb) in a PD-1/L1 reporter assay. Together these data demonstrate the potential for MEDI5752 to inhibit CTLA-4 on TILs whilst sparing peripheral T cell populations and reducing toxicity. Furthermore, profiling of MEDI5752 in a range of primary T cell activation assays reveals equivalent activity to a combination of parental PD-1 and CTLA-4 antibodies. MEDI5752 is rapidly internalised upon target binding with kinetics similar to the parental αCTLA-4 mAb reflecting the rapid recycling of this receptor. However, in contrast to an αCTLA-4 mAb (or an αPD-1 mAb), MEDI5752, by tethering CTLA-4 to PD-1, leads to the internalisation and subsequent degradation of PD-1. This novel mechanism of action further differentiates MEDI5752 from a combination of mAb's targeting PD-1 and CTLA-4. MEDI5752 is a novel monovalent bispecific which may provide an improved therapeutic index when compared to a combination of bivalent αPD-1 and αCTLA-4 mAb's, and could provide benefit in cancer indications. Citation Format: Simon J. Dovedi, Yariv Mazor, Matthew Elder, Sumati Hasani, Bo Wang, Suzanne Mosely, Desmond Jones, Anna Hansen, Chuning Yang, Yanli Wu, Ikbel Achour, Nick Durham, Gareth Browne, Thomas Murray, James Hair, Michelle Morrow, Godfrey Rainey, Maria Jure Kunkel, John Gooya, Daniel Freeman, Ronald Herbst, Robert Wilkinson. MEDI5752: A novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T-cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2776." @default.
• W2885128417 created "2018-08-22" @default.
• W2885128417 creator A5000886111 @default.
• W2885128417 creator A5001107705 @default.
• W2885128417 creator A5003061336 @default.
• W2885128417 creator A5006469058 @default.
• W2885128417 creator A5008226730 @default.
• W2885128417 creator A5012490271 @default.
• W2885128417 creator A5012930757 @default.
• W2885128417 creator A5017283178 @default.
• W2885128417 creator A5031787481 @default.
• W2885128417 creator A5032501148 @default.
• W2885128417 creator A5044215747 @default.
• W2885128417 creator A5049000845 @default.
• W2885128417 creator A5054089984 @default.
• W2885128417 creator A5054250640 @default.
• W2885128417 creator A5056168495 @default.
• W2885128417 creator A5058809239 @default.
• W2885128417 creator A5065854665 @default.
• W2885128417 creator A5070645277 @default.
• W2885128417 creator A5073399228 @default.
• W2885128417 creator A5083380214 @default.
• W2885128417 creator A5085976480 @default.
• W2885128417 creator A5091782689 @default.
• W2885128417 date "2018-07-01" @default.
• W2885128417 modified "2023-10-18" @default.
• W2885128417 title "Abstract 2776: MEDI5752: A novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T-cells" @default.
• W2885128417 doi "https://doi.org/10.1158/1538-7445.am2018-2776" @default.
• W2885128417 hasPublicationYear "2018" @default.
• W2885128417 type Work @default.
• W2885128417 sameAs 2885128417 @default.
• W2885128417 citedByCount "11" @default.
• W2885128417 countsByYear W28851284172019 @default.
• W2885128417 countsByYear W28851284172020 @default.
• W2885128417 countsByYear W28851284172021 @default.
• W2885128417 countsByYear W28851284172022 @default.
• W2885128417 countsByYear W28851284172023 @default.
• W2885128417 crossrefType "journal-article" @default.
• W2885128417 hasAuthorship W2885128417A5000886111 @default.
• W2885128417 hasAuthorship W2885128417A5001107705 @default.
• W2885128417 hasAuthorship W2885128417A5003061336 @default.
• W2885128417 hasAuthorship W2885128417A5006469058 @default.
• W2885128417 hasAuthorship W2885128417A5008226730 @default.
• W2885128417 hasAuthorship W2885128417A5012490271 @default.
• W2885128417 hasAuthorship W2885128417A5012930757 @default.
• W2885128417 hasAuthorship W2885128417A5017283178 @default.
• W2885128417 hasAuthorship W2885128417A5031787481 @default.
• W2885128417 hasAuthorship W2885128417A5032501148 @default.
• W2885128417 hasAuthorship W2885128417A5044215747 @default.
• W2885128417 hasAuthorship W2885128417A5049000845 @default.
• W2885128417 hasAuthorship W2885128417A5054089984 @default.
• W2885128417 hasAuthorship W2885128417A5054250640 @default.
• W2885128417 hasAuthorship W2885128417A5056168495 @default.
• W2885128417 hasAuthorship W2885128417A5058809239 @default.
• W2885128417 hasAuthorship W2885128417A5065854665 @default.
• W2885128417 hasAuthorship W2885128417A5070645277 @default.
• W2885128417 hasAuthorship W2885128417A5073399228 @default.
• W2885128417 hasAuthorship W2885128417A5083380214 @default.
• W2885128417 hasAuthorship W2885128417A5085976480 @default.
• W2885128417 hasAuthorship W2885128417A5091782689 @default.
• W2885128417 hasConcept C154317977 @default.
• W2885128417 hasConcept C159654299 @default.
• W2885128417 hasConcept C185592680 @default.
• W2885128417 hasConcept C202751555 @default.
• W2885128417 hasConcept C203014093 @default.
• W2885128417 hasConcept C21705690 @default.
• W2885128417 hasConcept C2776090121 @default.
• W2885128417 hasConcept C502942594 @default.
• W2885128417 hasConcept C51785407 @default.
• W2885128417 hasConcept C542903549 @default.
• W2885128417 hasConcept C55493867 @default.
• W2885128417 hasConcept C57992300 @default.
• W2885128417 hasConcept C71924100 @default.
• W2885128417 hasConcept C8891405 @default.
• W2885128417 hasConceptScore W2885128417C154317977 @default.
• W2885128417 hasConceptScore W2885128417C159654299 @default.
• W2885128417 hasConceptScore W2885128417C185592680 @default.
• W2885128417 hasConceptScore W2885128417C202751555 @default.
• W2885128417 hasConceptScore W2885128417C203014093 @default.
• W2885128417 hasConceptScore W2885128417C21705690 @default.
• W2885128417 hasConceptScore W2885128417C2776090121 @default.
• W2885128417 hasConceptScore W2885128417C502942594 @default.
• W2885128417 hasConceptScore W2885128417C51785407 @default.
• W2885128417 hasConceptScore W2885128417C542903549 @default.
• W2885128417 hasConceptScore W2885128417C55493867 @default.
• W2885128417 hasConceptScore W2885128417C57992300 @default.
• W2885128417 hasConceptScore W2885128417C71924100 @default.
• W2885128417 hasConceptScore W2885128417C8891405 @default.
• W2885128417 hasIssue "13_Supplement" @default.
• W2885128417 hasLocation W28851284171 @default.
• W2885128417 hasOpenAccess W2885128417 @default.
• W2885128417 hasPrimaryLocation W28851284171 @default.
• W2885128417 hasRelatedWork W1971852928 @default.
• W2885128417 hasRelatedWork W1991837516 @default.
• W2885128417 hasRelatedWork W2015747966 @default.
• W2885128417 hasRelatedWork W2066251089 @default.
• W2885128417 hasRelatedWork W2068084502 @default.
• W2885128417 hasRelatedWork W2509717993 @default.

• next